Understanding painful symptomatic diabetic neuropathy

Practical Diabetes International

Volumn 21, Issue 4, 2004, Pages 157-161

  Boulton, Andrew J M ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes education; Diabetic neuropathy; Dysaesthetic pain; Foot ulceration; Gabapentin; Glycaemic control; Nervous system; Tricyclics

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIOXIDANT; CAPSAICIN; CARBAMAZEPINE; GABAPENTIN; GLUCOSE; IMIPRAMINE; LAMOTRIGINE; LIDOCAINE; MEXILETINE; NORADRENALIN; OPIATE; PHENYTOIN; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUPUNCTURE; CLINICAL TRIAL; COMPREHENSION; DIABETES CONTROL; DIABETIC NEUROPATHY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECG ABNORMALITY; ELECTROSTIMULATION THERAPY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERALGESIA; LETHARGY; LICENSING; LONG TERM CARE; NEUROPATHIC PAIN; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHYSICAL EXAMINATION; PHYSIOTHERAPY; REVIEW; XEROSTOMIA;

EID: 2442717631     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/pdi.625     Document Type: Review

References (49)

1. Harris MI, Hadden WC, Knowler WC, et al. Prevalence of diabetes and impaired glucose tolerance in U.S. population aged 20-74 yr. Diabetes 1987; 86: 523-534.
2. Amos AF, McCarthy DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med 1997; 14: S1-S85.
3. Dyck PJ, Kratz KM, Karnes JL, et al. Prevalence by staged severity of various types of diabetic neuropathy, nephropathy and retinopathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-824.
4. Young MJ, Boulton AJM, Williams DRR, et al. A multi-centre study of the prevalence of diabetic neuropathy in patients attending UK diabetic clinics. Diabetologia 1993; 36: 150-154.
5. Cabezas-Cerrato J. The prevalence of diabetic neuropathy in Spain: a study in primary care and hospital clinic groups. Diabetologia 1998; 41: 1263-1269.
6. Boulton AJM. Treatment of symptomatic diabetic neuropathy. Diabetes-Metab Res 2003; 19: S16-S21.
7. Canal N, Nemmi R. Autoimmunity and diabetic neuropathy. Clin Neurosci 1997; 4: 371-373.
8. Tesfaye S, Malik RA, Ward JD. Vascular factors in diabetic neuropathy. Diabetologia 1994; 37: 847-854.
9. Malik RA, Masson EA, Sharma AK, et al. Hypoxic neuropathy: relevance to human diabetic neuropathy. Diabetologia 1990; 33: 311-318.
10. Wright RA, Nukada H. Vascular and metabolic factors in the pathogenesis of experiemental diabetic neuropathy in mature rats. Brain 1994; 117(Pt 6): 1395-1407.
11. Powell HC, Rosoff J, Myers RR. Microangiopathy in human diabetic neuropathy. Acta Neuropathol 1985; 68: 295-305.
12. Kapur D. Neuropathic pain and diabetes. Diabetes-Metab Res 2003; 19: S9-S15.
13. Boulton AJM, Malik RA. Diabetic neuropathy. Med Clin N Am 1998; 82: 909-927.
14. Jude EB, Boulton AJM. End-stage complications of diabetic neuropathy. Diabetes Rev 1999; 7: 395-411.
15. Apfel SC, Asbury AK, Bril V, et al. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci 2001; 189: 3-5.
16. Vileikye L, Peyrot M, Bundy EC, et al. The development and validation of a neuropathy and foot ulcer - specific quality of life instrument. Diabetes Care 2003; 26: 2549-2555.
17. Ziegler D, Relijanovic M, Mehnert H, et al. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol 1999; 107: 421-430.
18. Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose-reductase inhibitor for diabetic peripheral neuropathy: 1 52 week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001; 24: 1776-1782.
19. Ziegler D, Gries FA. Alpha lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuroapathy. Diabetes 1997: 46(Suppl 2): S62-S66.
20. Boulton AJM. What causes neuropathic pain? J Diabetes Complicat 1992; 6: 58-63.
21. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms and management. Lancet 1999; 353: 1959-1964.
22. UKPDS 33. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and the risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853.
23. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progressions of neuropathy. Ann Intern Med 1995; 122: 561-568.
24. Morley GK, Mooradian AD, Leine AS, et al. Mechanism of pain in diabetic peripheral neuropathy: effect of glucose on pain perception in humans. Am J Med 1984; 77: 79-82.
25. Burchiel KJ, Russell LC, Lee RP, et al. Spontaneous activity of primary afferent activity in diabetic BB/wistar rats: a possible mechanism of chronic diabetic neuropathic pain. Diabetes. 1985; 36: 1210-1213.
26. Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001; 24: 1225-1228.
27. Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance. Diabetes Care 2001; 24: 1448-1451
28. Oyibo SO, Prasad YDM, Jackson NJ, et al. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabetic Med 2002; 19: 870-873.
29. Kennedy WR, Navarro X, Goetz FC, et al. Effect of pancreas transplantation on diabetic neuropathy. N Engl J Med 1990; 322: 1031-1037.
30. Clement S. Diabetes self-management education. Diabetes Care 1995; 18: 1204-1214.
31. Mazucca SA, Moorman NH, Wheeler ML, et al. The diabetes education study: A controlled trial of the effects of diabetes patient education. Diabetes Care 1986; 9: 1-10.
32. Raz I, Soskolne V, Stem P. Influence of small-group education on glucose homeostasis in NIDDM. Diabetes Care 1988; 11: 67-71.
33. Gruesser M, Bott U, Ellermann P, et al. Evaluation of a structured treatment and teaching program for non-insulin-treated type II diabetic outpatients in Germany after the nationwide introduction of reimbursement policy for physicians. Diabetes Care 1993; 16: 1268-1275.
34. McQuay H, Carroll D, Jadad AR, et al. Anticonvulsant drugs for the management of pain: a systematic review. BMJ 1995; 311: 1047-1052.
35. Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 2002; 6(Suppl A): 61-68.
36. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831-1836.
37. Hermstreet B, Lapointe M. Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy. Clin Therapeutics 2001; 23: 520-531.
38. Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain 2001; 17: 287-295.
39. McCleane GJ. Lamotrigine in the management of neuropathic pain: A review of the literature. Clin J Pain 2000; 16: 321-326.
40. Boulton AJM. Current and emerging treatments for the diabetic neuropathies. Diabetes Reviews 1999; 7: 279-286.
41. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline and fluoxetine on pain relief in diabetic neuropathy. N Engl J Med 1992; 326: 1250-1256.
42. Dejgard A, Petersen P, Kastrup J. Mexiletine for the treatment of chronic painful diabetic neuropathy. Lancet 1988; 1: 9-11.
43. Oskarsson P, Ljunggren J-G, Lins P-E, et al. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. Diabetes Care 1997; 20: 1594-1597.
44. Jarvis B, Coukell AJ. Mexiletine: a review of its therapeutic use in painful diabetic neuropathy. Drugs 1998; 56: 691-707.
45. Harati Y, Gooch C, Swenson M, et al. Double-blind randomised trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50: 1841-1846.
46. Ziegler D. Pharmacological treatment of painful diabetic neuropathy. In Clinical Management of Diabetic Neuropathy. Veves A (ed). Totawa, NJ: Humana Press, 1998; 147-168.
47. Zhang WY, Wan Po AL. The effectiveness of topically applied capsaicin: a meta-analysis. Eur J Clin Pharm 1994; 46: 517-522.
48. Tesfaye S, Watt J, Benbow SJ, et al. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet 1996; 348: 1696-1701.
49. Abusaisha BB, Constanzi JB, Boulton AJM. Acupuncture for the treatment of chronic painful diabetic neuropathy: a long-term study. Diabetes Research & Clin Pract 1998; 39: 115-121.